Zynerba Pharmaceuticals, Inc. (ZYNE)
$0.5829
-0.04 (-6.91%)
Rating:
Recommendation:
Neutral
| Symbol | ZYNE |
|---|---|
| Price | $0.5829 |
| Beta | 1.724 |
| Volume Avg. | 0.33M |
| Market Cap | 27.433M |
| Shares () | - |
| 52 Week Range | 0.49-2.94 |
| 1y Target Est | - |
| DCF Unlevered | ZYNE DCF -> | |
|---|---|---|
| DCF Levered | ZYNE LDCF -> | |
| ROE | -58.25% | Strong Sell |
| ROA | -57.46% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 18.22% | Neutral |
| P/E | - | |
| P/B | 0.48 | Neutral |
Latest ZYNE news
About
Download (Excel)Mr. Armando Anido
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Global Market
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.